SEC Filing Analysis: Acrivon Therapeutics, Inc. (ACRV)

Executive Summary

• Trading Significance: Low
• Key Takeaway: Michaela Levin filed an initial Form 3 reporting no initial beneficial ownership of Acrivon Therapeutics securities upon becoming an insider as Chief Business Officer.
• Market Impact: Neutral; standard administrative compliance filing with zero share turnover.

Company Information

Field	Value
Company	Acrivon Therapeutics, Inc.
Ticker Symbol	ACRV
CIK	0001781174
Industry	Pharmaceutical Preparations

Insider Information

Field	Value
Name	Levin Michaela
CIK	0002151012
Title/Position	Chief Business Officer
Relationship	Officer

Transaction Details

Field	Value
Form Type	3
Event Date	2026-08-31
Security Type	N/A
Shares Transacted	0
Price Per Share	N/A
Total Value	$0.00
Shares Owned After	0
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0.00
% of Market Cap ($90.00M)	0.00%
Shares Transacted	0
% of Shares Outstanding (42.80M)	0.00%
Post-Transaction Ownership	0 shares (0.00%)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: With a market capitalization of approximately $90 million and 42.8 million shares outstanding, this filing carries no direct balance sheet or share capital dilution impact.
• Ownership Concentration: The reporting officer currently holds 0% beneficial ownership in ACRV equity.

Market Impact Analysis

• Direction: Neutral
• Reasoning: Purely procedural Section 16 disclosure establishing insider reporting baseline with no open-market transactions or equity grants included.
• Expected Volume Impact: None
• Sentiment Indicator: Neutral

Additional Context

• Timing: Effective event date of August 31, 2026, filed on September 2, 2026.
• Special Circumstances: Includes an executed Power of Attorney appointing company legal and executive staff as attorneys-in-fact for future Section 16 and Rule 144 filings.